Loading page…

Parmax Pharma Ltd (PARMAX) · mywealthgrid

About

Parmax Pharma Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹51 Cr

P/E

67.5×

P/B

—

Dividend yield

ROE

—

ROCE

-83%

Debt / equity

—

OPM

-30.1%

EPS (TTM)

₹2.0

Book value

₹-16.6

52-week high

₹137.8

52-week low

₹25.2

₹137.8+278.2%1Y

Beta

0.34

Damps index moves

Volatility (1y)

78.8%

Annualised, daily returns

RSI (14)

100

Overbought territory

Rel. strength (1y)

259.9%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Outperformed the universe by 259.9% over 1 year

Cons

−Low return on equity of -64.2% (3-yr avg)
−Revenue shrank over the last 5 years (-14.3% a year)
−Weak interest coverage of -3.7×
−Expensive at 67.5× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

43/100

Business quality: 0
Growth: 50
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	12	12	21	26	18	15	11	28	12
COGS	-6	-5	-11	13	7	5	7	22	10
Gross profit	—	—	—	13	12	10	4	7	2
	16	16	30	9	9	8	7	6	6
	1	1	2	3	3	2	-3	0	-4
OPM %	9.1%	9.4%	8.4%	13%	14%	14.6%	-30.6%	0.9%	-30.1%
Depreciation	1	1	1	2	2	2	2	1	1
Interest	—	0	0	0	0	0	1	1	1
	0	0	0	0	0	0	0	-1	0
Profit before tax	0	0	1	1	0	0	-6	-2	-6
Tax	—	—	—	0	0	0	0	-0	-2
Tax %	—	—	—	37.2%	53.3%	300%	1.6%	-12.6%	-28.9%
	0	0	0	1	0	-0	-6	-2	-4
PAT margin %	0%	0.7%	2.1%	2.9%	0.8%	-0.7%	-52%	-7.4%	-34.4%
EPS (₹)	0	0.2	-1.3	2	0.4	-0.3	—	-5.6	-11.1
EPS adjusted (₹)	—	—	—	1.7	0.3	-0.2	-12.9	-4.7	-9.4
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	4	4	4	4	4
Reserves	1	2	1	-4	-6	-11
Minority interest	—	—	0	0	—	—
	5	5	4	6	8	12
	11	7	7	9	13	23
Total equity & liabilities	23	18	18	15	19	28
	11	10	10	9	8	8
CWIP	—	—	—	0	0	0
Investments	0	0	0	0	0	0
	12	8	8	6	10	20
Total assets	23	18	18	15	19	28

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	1	0	-0	-1	-2
	-3	-2	-1	-2	-1	-1
	0	-1	-0	1	1	4
Net cash flow	1	-2	-1	-0	0	1
Free cash flow	0	-1	-1	-2	-1	-3
CFO / Operating profit %	103.5%	29.3%	14.7%	—	-264%	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	48.7%	63.2%	64.4%	36.2%	23.6%	18.4%
EBITDA margin %	9.4%	8.4%	13%	14%	14.6%	-30.6%	0.9%	-30.1%
EBIT margin %	0.8%	3.6%	5.6%	3.5%	2.4%	-46.1%	-2.8%	-38.4%
PAT margin %	0.7%	2.1%	2.9%	0.8%	-0.7%	-52%	-7.4%	-34.4%
Working capital
Receivable days	—	—	23	14	15	60	17	95
Inventory days	—	—	107	155	287	124	56	290
Payable days	—	—	270	300	310	383	173	530
NWC days	—	—	-139	-132	-9	-199	-101	-145
Leverage
Current ratio	—	—	0.94	0.9	1.05	0.63	0.77	0.74
Debt to EBITDA	—	—	1.59	1.77	1.99	—	30.8	—
Debt to equity	—	—	0.93	0.76	0.77	59.1	-3.87	-1.87
Interest coverage	3.7	6.5	4.5	1.8	1.1	-8.1	-1.3	-3.7
Asset turnover	—	—	1.15	1.02	0.88	0.72	1.5	0.43
Return ratios
Return on assets %	—	—	3.3%	0.8%	-0.6%	-37.5%	-11.1%	-14.8%
Return on capital employed %	—	—	13.6%	6.2%	3.9%	-60.8%	-12.5%	-83%
Return on equity %	—	—	12.9%	2.3%	-1.7%	-5,750%	105%	67.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	30.8%	30.8%	30.83%	30.8%	30.8%	30.8%	30.8%	30.8%	30.8%	30.8%	30.8%	30.8%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	69.2%	69.2%	69.17%	69.2%	69.2%	69.2%	69.2%	69.2%	69.2%	69.2%	69.2%	69.2%
No. of shareholders	—	—	—	—	—	—	—	—	2,399	2,393	2,388	2,273

Promoter holding up 0 percentage points since Sep 2023.

15 deals · 23 Jun 2026 – 24 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
24 Aug 2026	RAJESH JOSEPH	Bulk	BSE	Buy	20,000	₹131.15	₹0.26 Cr
5 Aug 2026	RAJESH JOSEPH	Bulk	BSE	Buy	55,751	₹100.63	₹0.56 Cr
5 Aug 2026	NEO APEX SHARE BROKING SERVICES LLP	Bulk	BSE	Sell	30,000	₹101.65	₹0.30 Cr
31 Jul 2026	PARESH DHIRAJLAL SHAH	Bulk	BSE	Sell	25,427	₹104.78	₹0.27 Cr
30 Jul 2026	GUTTIKONDA VARA LAKSHMI	Bulk	BSE	Sell	87,547	₹111.00	₹0.97 Cr
30 Jul 2026	PARESH DHIRAJLAL SHAH	Bulk	BSE	Buy	30,000	₹111.00	₹0.33 Cr
30 Jul 2026	NEO APEX SHARE BROKING SERVICES LLP	Bulk	BSE	Buy	30,000	₹111.00	₹0.33 Cr
27 Jul 2026	GUTTIKONDA VARA LAKSHMI	Bulk	BSE	Buy	99,000	₹100.78	₹1.00 Cr
27 Jul 2026	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	32,849	₹100.78	₹0.33 Cr
27 Jul 2026	NEO APEX SHARE BROKING SERVICES LLP	Bulk	BSE	Sell	25,790	₹100.78	₹0.26 Cr

1–10 of 15

1 / 2

Ms. Ami R ShahIndependent Director
Keyur D VoraChief Financial Officer
Umang A. GosaliaWhole Time Director
Nikhil UchatIndependent Director
Ms. Bhakti AgheraCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Parmax Pharma Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

24 announcementsExport CSV

1 Oct 2026, 7:52 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

Loading announcements…

Date	Category	Subject	Filing
1 Oct 2026, 7:52 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
29 Sept 2026, 7:55 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
29 Sept 2026, 10:04 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
28 Sept 2026, 1:32 pm	Company Update General	Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company	PDF
9 Sept 2026, 9:29 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
7 Sept 2026, 8:59 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
7 Sept 2026, 8:52 pm	AGM/EGM AGM	Notice Of Annual General Meeting	PDF
2 Sept 2026, 10:47 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	PDF

Parmax Pharma Ltd

Parmax Pharma Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

Announcements

Not in the F&O segment

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Stock price CAGR

Return on equity

Parmax Pharma Ltd

Parmax Pharma Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Not in the F&O segment

Board meetings1

Ratio timeline

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity

1

1